Next Article in Journal
Eastern Canadian Colorectal Cancer Consensus Conference: Standards of Care for the Treatment of Patients with Rectal, Pancreatic, and Gastrointestinal Stromal Tumours and Pancreatic Neuroendocrine Tumours
Previous Article in Journal
Denosumab and Giant Cell Tumour of Bone—A Review and Future Management Considerations
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 20
Issue 5
10.3747/co.20.1357
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Chemotherapy (Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) in Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma: A Clinical Practice Guideline

by
A.A. Gupta
1,
X. Yao
2,*,
S. Verma
3,
H. Mackay
4 and
L. Hopkins
5 on behalf of the Sarcoma Disease Site Group and the Gynecology Cancer Disease Site Group
1
Department of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
2
Cancer Care Ontario, Program in Evidence-Based Care, Department of Oncology, McMaster University, Hamilton, ON, Canada
3
Department of Medical Oncology, The Ottawa Hospital Regional Cancer Centre, Ottawa, ON, Canada
4
Department of Medical Oncology, University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
5
Department of Obstetrics and Gynecology, The Ottawa Hospital, Ottawa, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2013, 20(5), 448-454; https://doi.org/10.3747/co.20.1357
Submission received: 2 July 2013 / Revised: 3 August 2013 / Accepted: 4 September 2013 / Published: 1 October 2013

Abstract

Questions: Does chemotherapy—that is, gemcitabine, gemcitabine plus docetaxel, doxorubicin, or trabectedin—improve clinical outcomes in women with inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma (lms)? Is there a difference in the tumour response rate to chemotherapy between recurrent pelvic disease and extrapelvic metastases in the target patients? Methods: This guideline was developed by Cancer Care Ontario’s Program in Evidence-Based Care, the Sarcoma Disease Site Group (dsg), and the Gynecologic Cancer dsg. The core methodology was the systematic review. The medline and embase databases (2004 to June 2011), the Cochrane Library, main guideline Web sites, and relevant annual meeting abstracts (2005–2010) were searched. Internal and external reviews were conducted, with final approval by the dsgs and the Program in Evidence-Based Care. Clinical Practice Guideline: Based on currently available evidence from the medical literature (four single-arm phase ii studies, one arm of a randomized controlled trial, and one abstract), doxorubicin alone, gemcitabine alone, or gemcitabine plus docetaxel may be treatment options in first- or second-line therapy (or both) for women with inoperable, locally advanced, recurrent, or metastatic uterine lms. Hematologic toxicity is common and should be monitored, and granulocyte colony–stimulating factor should be considered when gemcitabine plus docetaxel is used. Other toxicities, such as neurotoxicity, pulmonary toxicity, and cardiovascular toxicity should be monitored. No recommendation is made for or against the use of trabectedin in the targeted patients. No data were available concerning differences in response in recurrent pelvic disease or extrapelvic metastases, or concerning quality of life.
Keywords: chemotherapy; clinical practice guideline; uterine leiomyosarcoma chemotherapy; clinical practice guideline; uterine leiomyosarcoma

Share and Cite

MDPI and ACS Style

Gupta, A.A.; Yao, X.; Verma, S.; Mackay, H.; Hopkins, L., on behalf of the Sarcoma Disease Site Group and the Gynecology Cancer Disease Site Group. Chemotherapy (Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) in Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma: A Clinical Practice Guideline. Curr. Oncol. 2013, 20, 448-454. https://doi.org/10.3747/co.20.1357

AMA Style

Gupta AA, Yao X, Verma S, Mackay H, Hopkins L on behalf of the Sarcoma Disease Site Group and the Gynecology Cancer Disease Site Group. Chemotherapy (Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) in Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma: A Clinical Practice Guideline. Current Oncology. 2013; 20(5):448-454. https://doi.org/10.3747/co.20.1357

Chicago/Turabian Style

Gupta, A.A., X. Yao, S. Verma, H. Mackay, and L. Hopkins on behalf of the Sarcoma Disease Site Group and the Gynecology Cancer Disease Site Group. 2013. "Chemotherapy (Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) in Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma: A Clinical Practice Guideline" Current Oncology 20, no. 5: 448-454. https://doi.org/10.3747/co.20.1357

APA Style

Gupta, A. A., Yao, X., Verma, S., Mackay, H., & Hopkins, L., on behalf of the Sarcoma Disease Site Group and the Gynecology Cancer Disease Site Group. (2013). Chemotherapy (Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) in Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma: A Clinical Practice Guideline. Current Oncology, 20(5), 448-454. https://doi.org/10.3747/co.20.1357

Article Metrics

Back to TopTop